STERIS to Buy Xodus Medical for $2.1 Billion, Mostly With Debt
STERIS Corporation has agreed to pay $2.1 billion for all of Xodus Medical. The agreement was disclosed on Oct. 12, 2026, with STERIS as buyer and Xodus Medical as target. Investing.com
The purchase covers 100% of the equity, or all shares. That leaves no minority owners, and STERIS would hold full economic interest and voting power from closing, subject only to the deal closing as announced. STERIS STERIS is a leading provider of infection prevention and other procedural products and services. STERIS The named buyer is STERIS Corporation, and the deal is an equity purchase, buying the company itself, rather than an asset purchase of selected items.
Financing is expected to be primarily debt, or mostly borrowed money. The close is anticipated by December 31, 2026. Yahoo Finance Announcement to expected close is roughly eleven weeks, for funding, settlement and transfer of the shares.
The broader picture for savers and investors is the balance sheet effect. Buying all shares mostly with debt increases leverage, the amount of debt carried for the size of the business, without adding new shares. That keeps current shareholders' percentage ownership intact. It swaps the dilution of a share issue for fixed loan payments and refinancing risk. The word primarily matters. It means debt covers most of the $2.1 billion, with room for cash on hand or other sources for the rest, though the split was not disclosed. Lenders now focus on tenor, how long loans run, pricing, the interest cost, covenants, the loan rules, and whether permanent loans are already set or must be arranged before year-end.
Looking at what this means for execution, price certainty helps one side of planning and funding pressure hurts the other. A fixed $2.1 billion price removes guesswork on price. Attention shifts to debt-market capacity and syndication risk, whether banks can sell the loans on, between mid-October and late December. A short gap means less time with finances in limbo. It also leaves limited time to renegotiate or replace loan facilities before the Dec. 31 date if markets shift.
In my view, the thin disclosure shifts focus to cash after closing. With more debt, the open questions for credit and equity holders are how fast STERIS can pay debt down, how steady operating cash flow is from the combined consumables and procedural business, and how free cash flow, cash left after running costs, is split between debt repayment, capital spending and payouts. None of those details were in the announced terms. What is known is the direction: a larger company, higher gross debt, and full ownership of Xodus Medical if the deal closes on schedule.
